Business

Mana Capital Acquisition Corp. Announces Effectiveness of Registration Statement and October 25, 2022 Special Meeting of Stockholders to Approve Business Combination with Cardio Diagnostics, Inc.

DOVER, Del.--(BUSINESS WIRE)-- Mana Capital Acquisition Corp. (“Mana Capital”) (Nasdaq: MAAQU; MAAQ; MAAQW; MAAQR), a publicly traded special purpose

articleCardio Diagnostics Holdings Inc.October 10, 20223/company/cardio-diagnostics-holdings-inc/news/mana-capital-acquisition-corp-announces-effectiveness-of-registration-statement-and-october-25-2022-special-meeting-of-stockholders-to-approve-business-combination-with-cardio-diagnostics-inc
Mana Capital Acquisition Corp. Announces Effectiveness of Registration Statement and October 25, 2022 Special Meeting of Stockholders to Approve Business Combination with Cardio Diagnostics, Inc.

About this update from Cardio Diagnostics Holdings Inc.

[{"type":"text","content":" DOVER, Del.--(BUSINESS WIRE)--\nMana Capital Acquisition Corp. (“Mana Capital”) (Nasdaq: MAAQU; MAAQ; MAAQW; MAAQR), a publicly traded special purpose acquisition company, today announced that its registration statement on Form S-4, relating to the previously announced business combination between Mana Capital and Cardio Diagnostics, Inc. (“Cardio”), a pioneering precision cardiovascular testing company, has been declared effective by the U.S. Securities and Exchange Commission. Mana Capital has mailed the definitive proxy statement/prospectus (the “Proxy Statement”) to stockholders of record as of the close of business on September 27, 2022. The Proxy Statement contains a notice and voting instruction form or a proxy card relating to the special meeting of Mana Capital’s stockholders (the “Special Meeting”). The definitive proxy statement is available at www.sec.gov.\n\nThe Special Meeting to approve the proposed business combination is scheduled to be held on October 25, 2022 at 10:00 a.m. Eastern Time via a virtual meeting format at https://www.cstproxy.com/manacapitalacquisition/2022. If the proposals at the Special Meeting are approved, the parties anticipate that the business combination will close promptly after the Special Meeting. Upon closing, the combined company will be called Cardio Diagnostics Holdings, Inc., and the combined entity will commence trading on the Nasdaq under the new ticker symbols “CDIO” and “CDIOW”. The closing of the Business Combination is subject to approval by Mana Capital’s shareholders and the satisfaction of other customary closing conditions.\n\nEvery stockholder’s vote FOR ALL proposals is important, regardless of the number of shares held. Accordingly, Mana Capital requests that each stockholder complete, sign, date and return a proxy card (online or by mail) as soon as possible and, if by internet, no later than 11:59 p.m. Eastern Time on October 24, 2022, to ensure that the stockholder's shares will be represented at the Special Meeting. Stockholders who hold shares in “street name” (i.e., those stockholders whose shares are held of record by a broker, bank or other nominee) should contact their broker, bank or nominee to ensure that their shares are voted.\n\nIf any Mana Capital stockholder has any questions or need assistance voting, please contact Advantage Proxy, Inc., our proxy so...

More updates from Cardio Diagnostics Holdings Inc.